Document Type : original article

Authors

1 Birjand Atherosclerosis and Coronary Artery Research Center, Associate Professor of Pediatric, Birjand University of Medical Sciences(BUMS), Birjand, Iran.

2 Assistante professor of Social Medicine, Birjand University of Medical Sciences(BUMS

3 Resident of Pediatrics, Department of Pediatrics, Faculty of Medicine. Birjand University of Medical Sciences, Birjand, South Khorasan Province, Iran.

10.22038/ijp.2023.74803.5365

Abstract

Introduction: Different drugs with different mechanisms have been used to remove iron overload in thalassemia patients. This study aimed to compare the effect of Nanojade with Deferoxamine in reducing serum ferritin levels.

Methods: This randomized clinical trial was conducted on 41 major thalassemia patients. Selected patients were allocated to two groups by the permuted block randomization method. The first group was treated with Deferasirox (Nanojade) and the second group was treated with Deferoxamine (Desferal). All patients received the drugs at 14 mg/kg. Blood samples were collected at baseline, after 3 and 6 months after intervention. The chi-square test, Mann-Whitney U-test, and Friedman test were used for analytical statistics at a significance level of 0.05.

Results: 51.9% of patients in the Nanojade group and 40% in the Desferal group were females. Before the intervention, no difference was observed in terms of basic and demographic information. Before the intervention, 3 months, and 6 months after the intervention, none of the blood parameters in the studied groups were significantly different (p> 0.05). The overall mean ferritin levels in the 6 months in both groups had a significant decrease (PDeferasirox = 0.001 vs PDeferoxamine = 0.043); However, in the comparison between the two groups, no significant difference was observed between the levels of ferritin and creatinine at any of the time point (p> 0.05).

Conclusions: Deferasirox oral tablet (Nanojade®) is as effective as injectable form (defroxamine (Desferal®)) in reducing serum ferritin in patients with beta-thalassemia major without causing nephrotoxic effects. Therefore, it can be a suitable alternative to its injectable form.

Keywords

Beta-thalassemia,, ,،Deferoxamine,, ,،Deferasirox,, ,،Nanojade,, ,،serum ferritin